Lonza Expands Strategic Collaboration with Leading U.S. Biopharmaceutical Company, Adding Two Biologic Programs for Commercial Production and Enhancing Manufacturing with N-1 Perfusion Technology

July 12, 2026

Lonza Press Release Switzerland

Overview

Lonza has announced an expanded strategic collaboration with a leading U.S. biopharmaceutical company, adding two new biologic programs for commercial production. This multi-year agreement leverages Lonza’s global multi-site network and advanced process intensification technologies, such as N-1 perfusion, reinforcing its long-term commitment to a diverse biopharmaceutical portfolio. This move further enhances its capacity for complex biologic supply.

In Depth

Key Findings

Lonza has announced a significant expansion of its strategic collaboration with a prominent U.S. biopharmaceutical company, adding two new biologic programs for commercial production. This multi-year agreement is poised to further solidify Lonza’s leadership in the biopharmaceutical industry by leveraging its extensive global manufacturing network and innovative process intensification technologies.

Technical / Clinical Details

This expanded partnership will fully utilize Lonza’s broad global network of manufacturing sites and cutting-edge process intensification technologies, including N-1 perfusion, which is a state-of-the-art technique in biopharmaceutical manufacturing. N-1 perfusion significantly enhances bioreactor productivity by achieving much higher cell densities during the early stages of the cell culture process. This results in reduced manufacturing times, lower production costs, and improved product quality and consistency. The two new biologic programs transitioning to commercial production have the potential to address a wide range of disease areas, clearly demonstrating Lonza’s long-term commitment to a diverse biopharmaceutical portfolio. The collaboration aims for both companies to work together to bring innovative therapies to patients more rapidly.

Background & Context

The biopharmaceutical market continues its sustained growth, driven by the emergence of new therapies for cancer, autoimmune diseases, rare diseases, and other conditions. Concurrently, there is a rising global demand for Contract Development and Manufacturing Organizations (CDMOs) with advanced manufacturing capabilities and technological expertise. Lonza, as a leading CDMO, is addressing this demand through strategic investments and partnerships. The adoption of process intensification technologies is particularly critical for overcoming manufacturing bottlenecks and shortening the timeline from biopharmaceutical development to commercialization. Such collaborations enable pharmaceutical companies to concentrate their resources on research and development while outsourcing manufacturing risks to specialized partners.

Strategic Significance & Outlook

The expansion of the strategic collaboration between Lonza and the U.S. biopharmaceutical company is expected to yield mutually beneficial outcomes for both parties and have a substantial impact on the broader biopharmaceutical industry. Lonza will strengthen its commercial production capacity for diverse biologics and further popularize advanced technologies like N-1 perfusion, thereby enhancing the efficiency and sustainability of biopharmaceutical manufacturing. This acceleration in new drug market entry is anticipated to improve access for patients with unmet medical needs. The partnership establishes a strong foundation for building long-term relationships and collectively driving future innovations in the sector.

Source: https://www.scbio.org/lonza-expands-strategic-collaboration-with-leading-us-biopharmaceutical-company/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.